Tenofovir versus lamivudine followed by tenofovir in severe exacerbation of hepatitis B: a randomized controlled study.
Sign Up to like & getrecommendations! Published in 2021 at "Antimicrobial agents and chemotherapy"
DOI: 10.1128/aac.01664-21
Abstract: Spontaneous severe acute exacerbation (SAE) is not uncommon in the natural history of chronic hepatitis B (CHB). Lamivudine (LAM) had the advantages of low price, quick onset, good efficacy and no drug resistance within 24… read more here.
Keywords: lamivudine; exacerbation; lam weeks; study ... See more keywords